HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.

Abstract
Effective stimulation of immune cells is crucial for the success of cancer immunotherapies. Current approaches to evaluate the efficiency of stimuli are mainly defined by known flow cytometry-based cell activation or cell maturation markers. This method however does not give a complete overview of the achieved activation state and may leave important side effects unnoticed. Here, we used an unbiased RNA sequencing (RNA-seq)-based approach to compare the capacity of four clinical-grade dendritic cell (DC) activation stimuli used to prepare DC-vaccines composed of various types of DC subsets; the already clinically applied GM-CSF and Frühsommer meningoencephalitis (FSME) prophylactic vaccine and the novel clinical grade adjuvants protamine-RNA complexes (pRNA) and CpG-P. We found that GM-CSF and pRNA had similar effects on their target cells, whereas pRNA and CpG-P induced stronger type I interferon (IFN) expression than FSME. In general, the pathways most affected by all stimuli were related to immune activity and cell migration. GM-CSF stimulation, however, also induced a significant increase of genes related to nonsense-mediated decay, indicating a possible deleterious effect of this stimulus. Taken together, the two novel stimuli appear to be promising alternatives. Our study demonstrates how RNA-seq based investigation of changes in a large number of genes and gene groups can be exploited for fast and unbiased, global evaluation of clinical-grade stimuli, as opposed to the general limited evaluation of a pre-specified set of genes, by which one might miss important biological effects that are detrimental for vaccine efficacy.
AuthorsTill S M Mathan, Johannes Textor, Annette E Sköld, Inge Reinieren-Beeren, Tom van Oorschot, Mareke Brüning, Carl G Figdor, Sonja I Buschow, Ghaith Bakdash, I Jolanda M de Vries
JournalOncotarget (Oncotarget) Vol. 8 Issue 12 Pg. 19879-19893 (Mar 21 2017) ISSN: 1949-2553 [Electronic] United States
PMID28186996 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Antigens, CD1
  • CD1C protein, human
  • CPG-oligonucleotide
  • FSME-IMMUN vaccine
  • Glycoproteins
  • Interferon Type I
  • Oligodeoxyribonucleotides
  • Protamines
  • Vaccines
  • Viral Vaccines
  • RNA
  • Granulocyte-Macrophage Colony-Stimulating Factor
Topics
  • Adjuvants, Immunologic (pharmacology)
  • Antigens, CD1 (immunology, metabolism)
  • Cells, Cultured
  • Cluster Analysis
  • Dendritic Cells (drug effects, immunology, metabolism)
  • Flow Cytometry
  • Gene Expression Profiling (methods)
  • Gene Ontology
  • Glycoproteins (immunology, metabolism)
  • Granulocyte-Macrophage Colony-Stimulating Factor (immunology, pharmacology)
  • Humans
  • Immunotherapy (methods)
  • Interferon Type I (biosynthesis, genetics, immunology)
  • Oligodeoxyribonucleotides (immunology, pharmacology)
  • Protamines (immunology, pharmacology)
  • RNA (immunology, pharmacology)
  • Sequence Analysis, RNA (methods)
  • Transcriptome (drug effects, immunology)
  • Vaccines (immunology, therapeutic use)
  • Viral Vaccines (immunology, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: